<DOC>
	<DOCNO>NCT02136563</DOCNO>
	<brief_summary>This observational clinical research patient chronic kidney disease hemodialysis receive darbepoetin alfa treat diagnose renal anemia ; major objective explore novel erythropoiesis stimulating agent ( ESA ) response index association deterioration renal function well occurrence cardiovascular disease event .</brief_summary>
	<brief_title>Renal Prognosis Chronic Kidney Disease Patients With Hyporesponsive Anemia Erythropoiesis Stimulating Agents</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>1 . Patients plan start treatment darbepoetin alfa within 8 week enrollment , 2 . Patients eGFR &lt; 60 mL/min/1.73m2 late examination perform within 8 week enrollment , 3 . Patients hemoglobin level &lt; 11.0 g/dL late examination perform within 8 week enrollment , 4 . Patients age least 20 year old time provide informed consent , 5 . Patients voluntarily provide write informed consent participate study . 1 . Patients plan start hemodialysis renal transplant within 24 week enrollment , 2 . Patients history treatment ESA except one treat temporarily 12 week enrollment , 3 . Patients malignant tumor , hematological disease , hemorrhagic lesion , 4 . Patients hypersensitivity ESA ingredient thereof , 5 . Pregnant , lactate possibly pregnant woman wish become pregnant study period , 6 . Patients participate clinical study , 7 . Patients assess eligible study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Erythropoiesis stimulate agent response index</keyword>
	<keyword>Hyporesponsive anemia erythropoiesis stimulating agent</keyword>
	<keyword>Observational study</keyword>
</DOC>